Allogeneic CD19/BCMA-targeted CAR-γδT Cell Therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic CD19/BCMA-targeted CAR-γδT Cell Therapy, covering 2026-03-24 to 2026-03-24. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases [Phase 1]